GlassScriptPhysician profile
Jeffrey A German
NPI 1295751709
$5,828.48
in general payments reported to CMS, 2019-2025
36 companies · $798 in 2025
The $798 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $587 · 2021: $1,222 · 2022: $1,113 · 2023: $918 · 2024: $678 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,394.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $843.64 | 2020-2025 | |
| Novo Nordisk INC | $777.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.27 | 2019-2025 | Jardiance |
| Amgen INC. | $450.16 | 2019-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $390.87 | 2019-2025 | Gardasil 9, Dificid, Steglatro |
| Lilly USA, LLC | $385.55 | 2020-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $326.89 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $244.19 | 2019-2025 | |
| Glaxosmithkline, LLC. | $218.60 | 2019-2025 | Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $212.55 | 2019-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.91 | 2020-2025 | Xifaxan |
| Abbott Laboratories | $120.86 | 2022-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $118.98 | 2024-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $117.78 | 2019-2025 | Veozah |
| Allergan, INC. | $113.68 | 2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $90.73 | 2022 | |
| Orthofix Medical, INC. | $84.74 | 2023 | Physio-Stim |
| Sanofi-Aventis U.S. LLC | $81.24 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $74.97 | 2021-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $70.42 | 2020-2021 | |
| Exact Sciences Corporation | $62.70 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $57.24 | 2020-2021 | |
| Shire North American Group INC | $50.96 | 2019 | |
| Eisai INC. | $34.12 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $30.81 | 2021-2022 | |
| Horizon Therapeutics Plc | $24.20 | 2019 | |
| Ethicon US, LLC | $20.92 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.90 | 2024 | Voquezna |
| Abiomed | $18.14 | 2025 | |
| Corcept Therapeutics | $17.93 | 2025 | Korlym |
| Shield Therapeutics INC | $16.94 | 2025 | |
| Hologic Sales and Service, LLC | $16.58 | 2021 | |
| Neos Therapeutics, LP | $15.58 | 2019 | |
| Amarin Pharma, INC. | $14.53 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.62 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey German listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.